Added to YB: 2025-11-25
Pitch date: 2025-11-21
NRIX [bullish]
Nurix Therapeutics, Inc.
-6.95%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Market Cap
$1.6B
Pitch Price
$16.97
Price Target
24.31 (+54%)
Dividend
N/A
EV/EBITDA
-4.15
P/E
-5.11
EV/Sales
12.71
Sector
Biotechnology
Category
growth
A Small-Cap With Big-Pharma Backing – And a Lead Drug That Could Change Its Trajectory - Nurix Therapeutics, Inc.
NRIX: First-in-class brain-penetrant BTK degrader showing 80.9% ORR in resistant CLL, 84.2% in WM. Pivotal DAYBREAK trial launching H2 2025. FDA Fast Track + Orphan Drug status. $428M cash, partnerships w/ Gilead/Sanofi/Pfizer. Risk-weighted target $24.31 vs $15.33 (+58% upside).
Read full article (6 min)